 RESEARCH TRIANGLE PARK, N.C., Sept. 01, 2021 GLOBE NEWSWIRE -- BioCryst Pharmaceuticals, Inc. Nasdaq: BCRX today announced that the U.S. Department of Health and Human Services HHS has exercised its option to purchase an additional 10,000 doses of BioCrysts antiviral influenza therapy, RAPIVAB peramivir injection, for approximately 7 million. 